PEAK6 Group’s Cardiff Oncology CRDF Stock Holding History

PEAK6 Group’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-24	Closed	-$7K	–	4804
2014 Q4	$7K	Buy	+24	New	+$7.77K	﹤0.01%	4505

Other funds holding CRDF

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PEAK6 Group's CRDF Position: Q1 2015 in Review

PEAK6 Group sold out of Cardiff Oncology (CRDF) in Q1 2015, closing a stake of 162 shares — an estimated $50K sold.

PEAK6 Group first reported a position in CRDF in Q3 2014 and held it in 2 quarters. The position peaked at $50K in Q4 2014. 36 funds tracked by Wall St. Rank hold CRDF as of Q1 2015.

PEAK6 Group reported no remaining Cardiff Oncology position as of Q1 2015 after selling out during the quarter.
PEAK6 Group sold 162 Cardiff Oncology shares in Q1 2015, an estimated $50K.
PEAK6 Group first reported a position in Cardiff Oncology in Q3 2014 and held it in 2 quarters.
PEAK6 Group's Cardiff Oncology position peaked at $50K in Q4 2014.
36 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2015.

Based on PEAK6 Group's 13F filing for Q1 2015, filed 13 May 2015.